Diversified Trust Co Buys 18 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Diversified Trust Co grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,187 shares of the biopharmaceutical company’s stock after buying an additional 18 shares during the quarter. Diversified Trust Co’s holdings in Regeneron Pharmaceuticals were worth $1,142,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Norges Bank bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $932,571,000. International Assets Investment Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after purchasing an additional 590,314 shares during the period. Global Assets Advisory LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $339,594,000. First Trust Advisors LP increased its holdings in Regeneron Pharmaceuticals by 115.2% in the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after purchasing an additional 195,902 shares during the period. Finally, abrdn plc raised its position in Regeneron Pharmaceuticals by 552.8% during the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock worth $193,136,000 after purchasing an additional 186,215 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Argus raised their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. JPMorgan Chase & Co. upped their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Monday, June 17th. Truist Financial reissued a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,027.55.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $1,057.02 on Tuesday. The stock has a market cap of $116.47 billion, a price-to-earnings ratio of 31.23, a PEG ratio of 2.17 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $688.52 and a fifty-two week high of $1,081.17. The firm’s 50-day simple moving average is $984.27 and its 200 day simple moving average is $951.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 22,830 shares of the company’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the sale, the chief executive officer now owns 466,877 shares in the company, valued at approximately $457,179,964.71. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Leonard S. Schleifer sold 22,830 shares of the stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the sale, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the sale, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The disclosure for this sale can be found here. In the last three months, insiders have sold 61,971 shares of company stock worth $61,217,654. Corporate insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.